Rationale to Treat

  • D. H. Blankenhorn
  • H. N. Hodis
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 109)


The weight of evidence from primary and secondary prevention clinical trials indicates that reduction of low-density lipoprotein cholesterol (LDLC) levels by diets, drugs, or other means can decrease the incidence of fatal and nonfatal myocardial infarction. A series of angiographic trials have demonstrated that reduced mortality and morbidity from LDL-C reduction are attributable, at least in part, to stabilization and regression of coronary atherosclerosis in both native vascular beds and venous bypass grafts. These studies provide the rationale for treatment of hyperlipoproteinemia with the goal of preventing coronary heart disease. Evidence from human clinical trials is supported by an extensive series of experiments in atherosclerotic animals of many species, including nonhuman primates. This review of treatment rationale summarizes evidence from human mortality and morbidity-based trials, human angiographic trials, and experimental animal models.


Familial Hypercholesterolemia Nonfatal Myocardial Infarction Coronary Artery Lesion Atherogenic Diet Coronary Drug Project 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Armstrong ML, Megan MB (1972) Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res 30: 675–680PubMedGoogle Scholar
  2. Armstrong ML, Megan MB (1975) Arterial fibrous proteins in cynomolgus monkeys after atherogenic and regression diets. Circ Res 36: 256–261PubMedGoogle Scholar
  3. Armstrong ML, Warner ED et al. (1970) Regression of coronary atheromatosis in rhesus monkeys. Circ Res 27: 59–67PubMedGoogle Scholar
  4. Arntzenius AC, Kromhout D et al. (1985) Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med 312: 805–811PubMedCrossRefGoogle Scholar
  5. Barndt R JR, Blankenhorn DH et al. (1977) Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Intern Med 86: 139–146PubMedGoogle Scholar
  6. Basta LL, Williams C et al. (1976) Regression of atherosclerotic stenosing lesions of the renal arteries and spontaneous cure of systemic hypertension through control of hyperlipidemia. Am J Med 61: 420–423PubMedCrossRefGoogle Scholar
  7. Blankenhorn DH, Nessim SA el al. (1987) Beneficial effects of combined colestipol—niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257: 3233–3240PubMedCrossRefGoogle Scholar
  8. Blankenhorn DH, Alaupovic P et al. (1990) Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and non-lipid factors. Circulation 81: 470–476PubMedCrossRefGoogle Scholar
  9. Brensike JF, Levy RI et al. (1984) Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 69: 313–324PubMedCrossRefGoogle Scholar
  10. Brown G, Albers JJ et al. (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289–1298PubMedCrossRefGoogle Scholar
  11. Buchwald H, Varco RL et al. (1990) Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323: 946–955PubMedCrossRefGoogle Scholar
  12. Canner PL, Berge KG et al. (1986) Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Card 8: 1245–1255CrossRefGoogle Scholar
  13. Cashin-Hemphill L, Mack WJ et al. (1990) Beneficial effects of colestipol—niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 264: 3013–3017PubMedCrossRefGoogle Scholar
  14. Clarkson TB, King JS et al. (1973) Pathologic characteristics and composition of diet-aggravated atherosclerotic plaques during “regression”. Exp Mol Pathol 19: 267–283PubMedCrossRefGoogle Scholar
  15. Clarkson TB, Bond MG et al. (1984) A study of atherosclerosis regression in Macaca mulatta: V. Changes in abdominal aorta and carotid and coronary arteries from animals with atherosclerosis induced for 38 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol 41: 96–118PubMedCrossRefGoogle Scholar
  16. Cohn K, Sakai FJ et al. (1975) Effect of clofibrate on progression of coronary disease: a prospective angiographic study in man. Am Heart J 89: 591–598PubMedCrossRefGoogle Scholar
  17. Crawford DW, Sanmarco ME et al. (1979) Spatial reconstruction of human femoral atheromata showing regression. Am J Med 66: 784–789PubMedCrossRefGoogle Scholar
  18. Dayton S, Pearce ML et al. (1969) A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 40 [Suppl II]: 1–63Google Scholar
  19. DePalma RG, Hubay CA et al. (1970) Progression and regression of experimental atherosclerosis. Surg Gynecol Obstet 131: 633–647PubMedGoogle Scholar
  20. DePalma GR, Bellon EM et al. (1977) Approaches to evaluating regression of experimental atherosclerosis. Adv Exp Med Biol 82: 459–470PubMedGoogle Scholar
  21. DePalma RG, Klein L et al. (1980) Regression of atherosclerotic plaques in rhesus monkeys. Angiographic, morphologic, and angiochemical changes. Arch Surg 115: 1268–1278PubMedGoogle Scholar
  22. Duffield RGM, Miller NE et al. (1983) Treatment of hyperlipidemia retards progression of symptomatic femoral atherosclerosis. A randomized controlled trial. Lancet 1: 639–642CrossRefGoogle Scholar
  23. Erikson U, Helmius G et al. (1983) Measurement of atherosclerosis by arteriography and microdensitometry. Model and clinical investigations. In: Schettler G, Gotto AM et al. (eds) Atherosclerosis VI. Springer, Berlin Heidelberg New York, p 197Google Scholar
  24. Farrar DJ, Green HD et al. (1980) Reduction in pulse wave velocity and improvement of aortic distensibility accompanying regression of atherosclerosis in the rhesus monkey. Circ Res 47: 425–432PubMedGoogle Scholar
  25. Frick MH, Elo O et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317: 1237–1245PubMedCrossRefGoogle Scholar
  26. Fritz KE, Augustyn JM et al. (1975) Effect of moderate diet and clofibrate on regression of swine atherosclerosis. Circulation 52: 11–16Google Scholar
  27. Fritz KE, Augustyn JM et al. (1976) Regression of advanced atherosclerosis in swine. Arch Pathol Lab Med 100: 380–385PubMedGoogle Scholar
  28. Harrison DG, Armstrong ML et al. (1987) Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 80: 1808–1811PubMedCrossRefGoogle Scholar
  29. Heistad DD, Breese K et al. (1987) Cerebral vasconstrictor responses to serotonin after dietary treatment of atherosclerosis: implications for transient ischemic attacks. Stroke 18: 1068–1073PubMedCrossRefGoogle Scholar
  30. Hjermann I, Enger SC et al. (1970) The effect of dietary changes on high density lipoprotein cholesterol. The Oslo Study. Am J Med 66: 105–109CrossRefGoogle Scholar
  31. Horlick K, Katz LN (1949) Retrogression of atherosclerotic lesions on cessation of cholesterol feeding in the chick. J Lab Clin Med 34: 1427PubMedGoogle Scholar
  32. Kane JP, Malloy MJ et al. (1990) Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264: 3007–3012PubMedCrossRefGoogle Scholar
  33. Keller C, Spengel FA (1988) Changes of atherosclerosis of the carotid arteries due to severe familial hypercholesterolemia following long-term plasmapheresis, assessed by duplex scan. Klin Wochenschr 66: 149–152PubMedCrossRefGoogle Scholar
  34. Kramsch DM, Aspen AJ et al. (1981a) Reduction of coronary atherosclerosis by moderate conditioning exercise in monkeys on an atherogenic diet. N Engl J Med 305: 1483–1489CrossRefGoogle Scholar
  35. Kramsch DM, Aspen AJ et al. (1981b) Atherosclerosis: prevention by agents not affecting abnormal levels of blood lipids. Science 213: 1511–1512CrossRefGoogle Scholar
  36. Kuo PT, Hayase K et al. (1979) Use of combined diet and colestipol in long-term (71 years) treatment of patients with type II hyperlipoproteinemia. Circulation 59: 199–211PubMedGoogle Scholar
  37. Leren P (1970) The Oslo diet-heart study: eleven year report, Circulation 42: 935–942PubMedGoogle Scholar
  38. Levy RI, Brensike JF et al. (1984) The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study. Circulation 69: 325–337PubMedCrossRefGoogle Scholar
  39. Lipid Research Clinics Coronary Primary Prevention Trial (1984) Results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365–374CrossRefGoogle Scholar
  40. Malinow MR (1980) Atherosclerosis. Regression in nonhuman primates. Circulation 46: 311–320Google Scholar
  41. Malinow MR, McLaughlin P et al. (1978a) Effect of alfalfa meal on shrinkage (regression) of atherosclerotic plaques during cholesterol feeding in monkeys. Atherosclerosis 30: 27–43CrossRefGoogle Scholar
  42. Malinow MR, McLaughlin P et al. (1978b) Treatment of established atherosclerosis during cholesterol feeding in monkeys. Atherosclerosis 31: 185–193CrossRefGoogle Scholar
  43. Mendelsohn D, Mendelsohn L (1989) Effect of polyunsaturated fat on regression of atheroma in the non-human primate. S Afr Med J 76: 371–373PubMedGoogle Scholar
  44. Morin RJ, Bernick L et al. (1964) Effects of essential fatty acid deficiency and supplementation of atheroma formation and regression. J Atherosler Res 4: 387CrossRefGoogle Scholar
  45. Nash DT, Gensini G et al. (1982) Effect of lipid-lowering therapy on the progression of coronary atherosclerosis assessed by scheduled repetitive coronary arteriography. Int J Cardiol 2: 43–55PubMedCrossRefGoogle Scholar
  46. Newcastle Study (1971) Trial of clofibrate in the treatment of ischaemic heart disease: five-year study by a group of physicians of the Newcastle upon Tyne region. BMJ 4: 767–775CrossRefGoogle Scholar
  47. Nikkila EA, Viikinkoski P et al. (1984) Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Br Med J [Clin Res] 289 (6439): 220–223CrossRefGoogle Scholar
  48. Oliver MF, Heady JA et al. (1978) A cooperative trial in the primary prevention of ischemic heart disease using clofibrate. Br Heart J 40: 1069–1118CrossRefGoogle Scholar
  49. Ornish D, Brown SE et al. (1990) Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 336: 129–133PubMedCrossRefGoogle Scholar
  50. Ost RC, Stenson S (1967) Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid. Scand J Clin Lab Invest [Suppl] 99: 241–245Google Scholar
  51. Portman OW, Alexander M et al. (1967) Nutritional control of arterial lipid composition on squirrel monkeys. Major ester classes and types of phospholipids. J Nutr 91: 35PubMedGoogle Scholar
  52. Rafflenbeul W, Smith LR et al. (1979) Quantitative coronary arteriography. Coronary anatomy of patients with unstable angina pectoris reexamined 1 year after optimal medical therapy. Am J Cardiol 43: 699–707PubMedCrossRefGoogle Scholar
  53. Research Committee (1965) Low-fat diet in myocardial infarction: a controlled trial. Lancet I: 501–504Google Scholar
  54. Research Committee to the Medical Research Council (1968) Controlled trial of soya-bean oil in myocardial infarction. Lancet 1: 693–700Google Scholar
  55. Rose GA, Thomson WB et al. (1965) Corn oil in the treatment of ischaemic heart disease. BMJ 1: 1531–1533PubMedCrossRefGoogle Scholar
  56. Roth D, Kostuk WJ (1980) Noninvasive and invasive demonstration of spontaneous regression of coronary artery disease. Circulation 62: 888–896PubMedGoogle Scholar
  57. Schettler G (1979) Cardiovascular diseases during and after World War II: a comparison of the Federal Republic of Germany with other European countries. Prey Med 8: 581CrossRefGoogle Scholar
  58. Scottish Society Study (1971) Ischaemic heart disease: a secondary prevention trial using clofibrate. BMJ 4: 775–784CrossRefGoogle Scholar
  59. Srinivasan SR, Patton D et al. (1980) Lipid changes in atherosclerotic aortas of Macaca fascicularis after various regression regimens. Atherosclerosis 37: 591–601PubMedCrossRefGoogle Scholar
  60. Stary HC (1972) Progression and regression of experimental atherosclerosis in rhesus monkeys. In: Goldsmith EF, Morr-Hankowsky J (eds) Medical primatology. Karger, Basel, p 356Google Scholar
  61. Stein EA, Adolph R et al. (1986) Nonprogression of coronary artery atherosclerosis in homozygous familial hypercholesterolemia after 31 months of repetitive plasma exchange. Clin Cardiol 9: 115–119PubMedCrossRefGoogle Scholar
  62. Subbiah MT, Dicke BA et al. (1978) Regression of naturally occurring atherosclerotic lesions in pigeon aorta by intestinal bypass surgery. Atherosclerosis 31: 117PubMedCrossRefGoogle Scholar
  63. Terry EN, Rouen LR et al. (1976) Attempts to delay progression in occlusive atherosclerosis. Ann NY Acad Sci 275: 379–385PubMedCrossRefGoogle Scholar
  64. Thompson GR, Myant NB et al. (1980) Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br Heart J 43: 680–688PubMedCrossRefGoogle Scholar
  65. Tucker CF, Catsulis C et al. (1971) Regression of early cholesterol-induced aortic lesions in rhesus monkeys. Am J Pathol 65: 494–502Google Scholar
  66. Vesselinovitch D, Wissler RW et al. (1976) Reversal of advanced atherosclerosis in rhesus monkeys: I. Light-microscopic Studies. Atherosclerosis 23: 155–176CrossRefGoogle Scholar
  67. Vesselinovitch D, Wissler RW et al. (1978) The effect of diets with or without cholestryamine on the lesion components of atherosclerotic plaques. Fed Proc 37: 835Google Scholar
  68. Wilens SL (1947) The resorption of arterial atheromatous deposits in wasting disease. Am J Pathol 23: 793–804PubMedGoogle Scholar
  69. Wissler RW, Vesselinovitch D et al. (1975) Regression of severe atherosclerosis in cholestryamine treated rhesus monkeys with or without a low fat, low-cholesterol diet. Circulation 52:15–16Google Scholar
  70. Woodhill JM, Palmer AJ et al. (1978) Low fat, low cholesterol diet in secondary prevention of coronary heart disease. Adv Exp Med Biol 109: 317–330PubMedGoogle Scholar
  71. Yokoyama S, Yamamoto A et al. (1987) LDL-apheresis; potential procedure for prevention and regression of atheromatous vascular lesion. Jpn Circ J 51: 1116–1122PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • D. H. Blankenhorn
  • H. N. Hodis

There are no affiliations available

Personalised recommendations